Contract Development and Manufacturing Organizations (CDMOs) Market, Share, Growth, and Industry Analysis by Type (API Development, Manufacturing, and Drug Delivery) by Application (Pharmaceutical Company, Biotechnology Company, and Generic Company) Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET OVERVIEW

In 2026, the global Contract Development and Manufacturing Organizations (CDMOs) Market is estimated at USD 140.3 Billion. With consistent expansion, the market is projected to attain USD 333.4 Billion by 2035. The market is forecast to grow at a CAGR of 10% over the period from 2026 to 2035.

The global Contract Development and Manufacturing Organizations Market is expanding due to increasing outsourcing activities among pharmaceutical, biotechnology, and generic drug companies. Contract development and manufacturing organizations provide integrated services covering drug development, active pharmaceutical ingredient production, formulation, clinical supply manufacturing, and commercial-scale production. The market is benefiting from rising demand for specialized manufacturing capabilities, cost optimization strategies, and increasing complexity of drug development processes. Pharmaceutical companies are increasingly partnering with contract manufacturers to accelerate product launches and improve operational flexibility. Growing adoption of advanced manufacturing technologies, biologics production, and personalized medicine development is further strengthening demand for contract development and manufacturing organizations worldwide.

The USA Contract Development and Manufacturing Organizations Market is driven by strong pharmaceutical innovation, biotechnology expansion, and increasing outsourcing activities among drug developers. The country has a highly developed healthcare ecosystem with significant demand for advanced manufacturing services, including biologics production, cell and gene therapy manufacturing, and complex drug formulation. Pharmaceutical and biotechnology companies in the USA are increasingly collaborating with contract development and manufacturing organizations to reduce development timelines and manage production capacity requirements. Growing investments in domestic pharmaceutical manufacturing, advanced therapeutic development, and supply chain security are supporting market growth. The increasing need for specialized manufacturing expertise is encouraging companies to expand partnerships with contract manufacturing providers across the USA.

KEY FINDINGS

LATEST TRENDS

Growing Innovation and Collaboration Among Market Players to Sustain Market Development

The Contract Development and Manufacturing Organizations Market is experiencing significant transformation due to increasing demand for outsourced pharmaceutical development and manufacturing services. One of the major trends shaping the market is the growing adoption of biologics and advanced therapies. Pharmaceutical and biotechnology companies are increasingly outsourcing production of monoclonal antibodies, vaccines, cell therapies, and gene therapies to specialized contract manufacturing organizations with advanced capabilities.

Supply chain diversification has become another major trend in the Contract Development and Manufacturing Organizations Market. Pharmaceutical companies are seeking reliable manufacturing partners to reduce supply chain risks and improve production resilience. Regional manufacturing expansion is increasing as companies focus on strengthening local production capabilities. Sustainability initiatives are also gaining importance, with contract manufacturers implementing environmentally responsible production practices, energy-efficient technologies, and waste reduction strategies. The integration of digital quality management systems and advanced analytics is further improving manufacturing reliability and regulatory compliance across the pharmaceutical outsourcing industry.

Download Free Sample to learn more about this report

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SEGMENTATION

By Type

According to type, the market can be segmented into API Development, Manufacturing, and Drug Delivery. The API development segment is projected to dominate the market share during 2022-2028.

• API Development: The API Development segment represents a significant portion of the Contract Development and Manufacturing Organizations Market due to increasing demand for active pharmaceutical ingredient research, process development, and manufacturing support. Pharmaceutical companies frequently outsource API development activities to contract organizations to access specialized expertise, advanced facilities, and regulatory knowledge. This segment accounts for approximately 34% market share due to the critical importance of APIs in drug production and the growing complexity of chemical and biological compounds.

• Manufacturing: The Manufacturing segment dominates the Contract Development and Manufacturing Organizations Market due to extensive outsourcing of clinical and commercial drug production activities. This segment holds approximately 45% market share because pharmaceutical and biotechnology companies increasingly rely on contract manufacturers for large-scale production, formulation, packaging, and quality control services. Contract manufacturing organizations provide essential production capabilities for tablets, capsules, injectable drugs, biologics, and other pharmaceutical products.

• Drug Delivery: The Drug Delivery segment is gaining importance in the Contract Development and Manufacturing Organizations Market due to rising demand for innovative delivery systems and advanced formulations. This segment represents approximately 21% market share and includes specialized services related to formulation development, controlled-release technologies, injectable systems, and targeted drug delivery solutions. Increasing demand for personalized medicine and complex therapies is creating opportunities for contract organizations with advanced drug delivery capabilities. 

By Application 

Based on application, the market can be divided into Pharmaceutical Company, Biotechnology Company, Generic Company. The pharmaceutical company segment is anticipated to hold the maximum market share through 2028.

• Pharmaceutical Company: The Pharmaceutical Company segment represents the largest application category in the Contract Development and Manufacturing Organizations Market due to extensive outsourcing of research, development, and manufacturing activities. This segment accounts for approximately 52% market share as established pharmaceutical companies increasingly collaborate with contract organizations to improve efficiency and reduce production costs. Pharmaceutical companies use contract development and manufacturing organizations for API production, formulation development, clinical trial manufacturing, and commercial-scale production.

• Biotechnology Company: The Biotechnology Company segment is experiencing rapid growth in the Contract Development and Manufacturing Organizations Market due to increasing development of biologics, cell therapies, and gene therapies. This segment holds approximately 32% market share and is expanding as biotechnology companies require specialized manufacturing infrastructure and technical expertise. Biotechnology companies often rely on contract manufacturers because advanced biological products require complex production processes, specialized equipment, and strict quality controls. Contract organizations provide essential support throughout clinical development and commercialization stages. 

• Generic Company: The Generic Company segment contributes approximately 16% market share in the Contract Development and Manufacturing Organizations Market due to increasing demand for cost-effective pharmaceutical production. Generic drug manufacturers often collaborate with contract organizations to improve production efficiency, manage capacity requirements, and reduce operational expenses. Contract manufacturers support generic companies through API development, formulation services, manufacturing, and packaging solutions. Growing demand for affordable medicines and increasing healthcare access are supporting expansion of generic drug production. 

MARKET DYNAMICS

Driving Factor

Increasing pharmaceutical outsourcing and rising demand for specialized manufacturing services

The increasing adoption of outsourcing strategies by pharmaceutical and biotechnology companies is a major driver of the Contract Development and Manufacturing Organizations Market. Drug developers are increasingly partnering with contract organizations to access advanced manufacturing infrastructure, technical expertise, and regulatory support without requiring significant internal investment. The rising complexity of modern medicines, including biologics, gene therapies, and personalized treatments, is creating demand for specialized production capabilities.

Restraining Factor

High regulatory compliance requirements and complex manufacturing processes

Strict regulatory requirements represent a major restraint for the Contract Development and Manufacturing Organizations Market. Contract manufacturers must maintain high-quality production standards and comply with complex regulations governing pharmaceutical development and manufacturing activities. Meeting regulatory expectations requires continuous investment in advanced equipment, quality management systems, skilled professionals, and facility upgrades. Manufacturing biologics and advanced therapies involves complex processes that require specialized expertise and strict control measures.

Growth in biologics, cell therapies, and personalized medicine manufacturing

Opportunity

The increasing development of advanced therapeutic products creates significant opportunities for the Contract Development and Manufacturing Organizations Market. Biologics, cell and gene therapies, and personalized medicines require specialized manufacturing capabilities that many pharmaceutical companies prefer to outsource. Contract manufacturers with expertise in advanced production technologies are benefiting from rising demand for flexible and scalable solutions. The expansion of biotechnology research is increasing the need for development support, clinical manufacturing, and commercial production services.

Capacity limitations and increasing competition among contract manufacturers

Challenge

Limited manufacturing capacity and growing competition represent significant challenges in the Contract Development and Manufacturing Organizations Market. The increasing demand for outsourced pharmaceutical production has created pressure on contract manufacturers to expand facilities and improve production capabilities. Advanced therapies require specialized manufacturing environments, creating challenges related to infrastructure availability and technical expertise. Companies must continuously invest in facility expansion, technology upgrades, and workforce development to meet changing customer requirements.

• Download Free Sample to learn more about this report

•  

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET REGIONAL INSIGHTS

• North America

North America holds the largest share in the Contract Development and Manufacturing Organizations Market, accounting for approximately 38% market share due to its advanced pharmaceutical ecosystem, strong biotechnology sector, and high adoption of outsourcing strategies. The region is home to a large number of pharmaceutical and biotechnology companies that require specialized development and manufacturing services.

North American contract manufacturers are investing in advanced facilities, automation systems, and digital manufacturing technologies to strengthen their competitive position. The region is also focusing on supply chain security and domestic manufacturing expansion, creating additional opportunities for contract development and manufacturing organizations. The growing adoption of personalized medicine and advanced therapies is expected to further support market development. Increasing demand for flexible manufacturing solutions and specialized production capabilities continues to strengthen North America’s leadership position in the global Contract Development and Manufacturing Organizations Market.

• Europe

Europe represents a significant region in the Contract Development and Manufacturing Organizations Market, accounting for approximately 30% market share due to its strong pharmaceutical manufacturing infrastructure, advanced research capabilities, and established regulatory environment. The region has a long history of pharmaceutical innovation, making it a major hub for outsourced drug development and manufacturing services. Increasing demand for biologics, specialty medicines, and complex formulations is supporting the expansion of contract development and manufacturing organizations across European countries.

The region is benefiting from increasing partnerships between pharmaceutical companies and contract manufacturers. Growing healthcare expenditure, expanding research activities, and rising demand for personalized medicine are creating additional opportunities. Europe continues to maintain a strong position in the Contract Development and Manufacturing Organizations Market due to its technical expertise, manufacturing capabilities, and innovation-driven pharmaceutical ecosystem.

• Asia-Pacific

Asia-Pacific is the fastest-growing region in the Contract Development and Manufacturing Organizations Market, accounting for approximately 24% market share due to expanding pharmaceutical production, cost-effective manufacturing capabilities, and increasing investment in healthcare infrastructure. Countries such as China, India, Japan, South Korea, and Singapore are becoming important centers for pharmaceutical outsourcing activities.

The growth of biotechnology research, increasing healthcare investments, and rising demand for affordable medicines are creating significant opportunities in the region. Governments and private companies are supporting pharmaceutical manufacturing development, improving infrastructure, and encouraging innovation. The region is expected to experience strong market growth due to increasing outsourcing trends, expanding pharmaceutical production capacity, and growing demand for specialized manufacturing services. Asia-Pacific’s combination of manufacturing expertise, investment potential, and healthcare expansion continues to make it a key growth region for the Contract Development and Manufacturing Organizations Market.

• Middle East & Africa

The Middle East & Africa region accounts for approximately 5% market share in the Contract Development and Manufacturing Organizations Market and is gradually expanding due to increasing healthcare investments, pharmaceutical infrastructure development, and growing demand for local medicine production. Countries across the region are focusing on strengthening healthcare systems and reducing dependence on imported pharmaceutical products. The Middle East is witnessing increasing investment in pharmaceutical manufacturing facilities and healthcare innovation programs. Governments and private companies are encouraging local production capabilities, creating opportunities for contract development and manufacturing organizations.

Challenges such as limited manufacturing infrastructure, investment constraints, and regulatory variations may affect market expansion. However, increasing healthcare spending, pharmaceutical localization initiatives, and international collaborations are supporting gradual growth. The Middle East & Africa region is expected to continue developing as pharmaceutical companies seek new manufacturing locations and regional production capabilities. Increasing demand for affordable medicines and improved healthcare access will contribute to the expansion of the Contract Development and Manufacturing Organizations Market in this region.

• Rest of World

The Rest of World region accounts for approximately 3% market share in the Contract Development and Manufacturing Organizations Market and includes Latin America and other emerging pharmaceutical markets. The region is experiencing gradual growth due to increasing healthcare demand, pharmaceutical industry development, and rising adoption of outsourcing strategies. Latin American countries are investing in healthcare infrastructure improvements and expanding pharmaceutical manufacturing capabilities. Contract development and manufacturing organizations are gaining opportunities as local pharmaceutical companies seek external expertise for drug development, manufacturing, and regulatory support.

However, challenges such as limited advanced manufacturing infrastructure, economic fluctuations, and regulatory complexities can affect market development. Companies are addressing these issues through strategic partnerships, technology investments, and capacity expansion initiatives. The Rest of World region is expected to experience steady adoption of contract development and manufacturing services as pharmaceutical companies continue seeking efficient production models and expanded market access.

LIST OF TOP CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) COMPANIES

• Lonza
• Catalent
• Patheon (Thermo Fisher Scientific)
• Aenova
• Siegfried
• Recipharm
• Strides Shasun
• Piramal
• Metrics
• AMRI
• Famar
• WuXi AppTech
• Asymchem
• Porton
• Amatsigroup

Top 2 Companies With Highest Market Share

• Lonza: Accounted for approximately 17% of global CDMO market share due to strong biologics and cell therapy manufacturing capabilities.
• Catalent: Held nearly 14% market share supported by extensive pharmaceutical manufacturing and drug delivery service operations.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the Contract Development and Manufacturing Organizations Market is increasing as pharmaceutical and biotechnology companies continue expanding outsourcing strategies to improve efficiency, reduce development timelines, and access specialized manufacturing capabilities. Companies are investing in advanced production facilities, biologics manufacturing infrastructure, and digital technologies to support the growing demand for complex therapeutic products. The increasing development of monoclonal antibodies, cell therapies, gene therapies, and personalized medicines is creating significant investment opportunities for contract development and manufacturing organizations with advanced technical expertise.

Companies investing in digital manufacturing capabilities are positioned to support pharmaceutical customers seeking faster and more reliable production solutions. Strategic collaborations, facility expansions, and technology acquisitions are becoming important investment strategies in the Contract Development and Manufacturing Organizations Market. Organizations are focusing on strengthening capabilities in advanced therapies, specialized formulations, and integrated development services to capture increasing demand from global pharmaceutical and biotechnology companies.

NEW PRODUCT DEVELOPMENT

New product development in the Contract Development and Manufacturing Organizations Market is focused on improving manufacturing capabilities for complex therapies, enhancing production efficiency, and supporting innovation in pharmaceutical development. Contract organizations are developing advanced solutions for biologics, cell and gene therapies, personalized medicines, and specialty drug formulations to meet evolving healthcare requirements. A major area of innovation is the development of advanced biologics manufacturing platforms. Contract manufacturers are investing in improved bioprocessing technologies, single-use manufacturing systems, and automated production environments to support the growing demand for biologic medicines. 

Sustainable manufacturing development is also gaining attention, with contract organizations introducing environmentally efficient production methods, waste reduction initiatives, and energy-saving technologies. Companies are investing in flexible manufacturing platforms that support multiple product types and smaller production volumes. Future product development in the Contract Development and Manufacturing Organizations Market is expected to focus on automation, advanced therapeutic manufacturing, integrated development services, and innovative production technologies that enable faster and more efficient pharmaceutical commercialization.

FIVE RECENT DEVELOPMENTS 

• February 2023: Lonza expanded its advanced manufacturing capabilities with investments focused on biologics production and specialized pharmaceutical development services. The initiative strengthened its ability to support increasing demand for complex therapies, including biologics and advanced medicines. The expansion improved manufacturing capacity and supported pharmaceutical companies seeking reliable contract development and manufacturing partnerships.

• June 2023: Catalent introduced enhanced manufacturing capabilities for advanced drug delivery technologies and pharmaceutical development services. The development focused on improving formulation expertise, production efficiency, and support for complex therapeutic products. The initiative helped strengthen Catalent’s role in providing integrated development and manufacturing solutions for pharmaceutical and biotechnology companies.

• January 2024: WuXi AppTec expanded its pharmaceutical development and manufacturing infrastructure to support growing demand for outsourced services. The investment focused on increasing production capacity, improving technology capabilities, and supporting innovative drug development programs. The expansion enhanced the company’s ability to serve global pharmaceutical and biotechnology customers.

• September 2024: Thermo Fisher Scientific strengthened its contract manufacturing capabilities through expanded pharmaceutical production services. The initiative focused on improving manufacturing capacity, supporting biologics production, and enhancing supply chain reliability. The development supported growing demand for flexible outsourcing solutions among pharmaceutical companies.

• May 2025: Aenova introduced upgraded manufacturing solutions focused on advanced pharmaceutical production and digital quality management. The development aimed to improve operational efficiency, strengthen quality control processes, and support increasing demand for outsourced pharmaceutical manufacturing services. The initiative enhanced Aenova’s capabilities in serving global healthcare companies.

REPORT COVERAGE

The Contract Development and Manufacturing Organizations Market report provides comprehensive analysis of market size, growth trends, competitive landscape, segmentation, regional performance, and emerging opportunities. The report evaluates market dynamics influencing outsourcing activities across pharmaceutical, biotechnology, and generic drug manufacturing sectors. The study covers detailed segmentation by type, including API Development, Manufacturing, and Drug Delivery services, along with application analysis covering Pharmaceutical Company, Biotechnology Company, and Generic Company segments. It examines key factors driving market growth, including pharmaceutical outsourcing, biologics expansion, advanced therapy development, and demand for specialized manufacturing capabilities.

The competitive landscape section highlights leading contract development and manufacturing organizations, focusing on service capabilities, technology investments, facility expansions, and strategic developments. The report also includes recent industry developments between 2023 and 2025, covering manufacturing expansions, technology upgrades, and innovation initiatives. The report serves as a valuable resource for pharmaceutical companies, biotechnology firms, investors, suppliers, and industry stakeholders seeking detailed insights into market opportunities, competitive positioning, and future growth prospects within the global Contract Development and Manufacturing Organizations Market.